Gene

AR

androgen receptor

Explore in graph →CI-GENE-00011134HGNC:644 ENSG00000169083 NCBI 367 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (48)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–48 of 48 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
AR A234T1
(functional)	—UNRESOLVED	Functional	D	Supports Loss Of Function	3	submitted

Cohorts

Alteration frequency by cohort (163)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved163 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm

Literature

Linked publications (12)

25 per page, newest first.

pubmedPublishedShowing 1–12 of 12 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Integrative clinical genomics of advanced prostate cancer.
· Cell · 2015 · PMID 26000489 · validated civic_curation pubmed
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
· J Clin Oncol · 2019 · PMID 30865549 · validated civic_curation pubmed
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
· JAMA Oncol · 2016 · PMID 27262168 · validated civic_curation pubmed
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.
· JAMA Oncol · 2018 · PMID 29955787

AR AR alternative transcripts2
(oncogenic)	Malignant Prostate Neoplasm	Oncogenic	B	Supports Oncogenicity	4	submitted	EID12402 Analysing 101 samples of metastatic prostate cancer biopsy, a high friequency of structural variants in the AR gene were identified (23/101), comprising a heterogeneous mix of deletion, inversion, tra… (full text at CIViC) PMID 31932493 · Li et al., 2020 · Open in CIViC	civic
Abiraterone + EnzalutamideSubstitutes	Malignant Prostate Neoplasm	Predictive	B	Does Not Support Resistance	4	submitted	EID9578 In a clinical study including 168 patients treated with abiraterone or enzalutamide, a multivariate analysis including tumor burden and TP53 status show no significant correlation between AR-V1, AR-V2… (full text at CIViC) PMID 30209161 · De Laere et al., 2019 · Open in CIViC	civic

AR AR-V716
(prognostic)	Malignant Prostate Neoplasm	Prognostic	B	Supports Poor Outcome	3	submitted	EID12376 Analysis was performed on 224 advanced prostate cancer (PCA) patient samples which had clinical outcome information. Elevated PSA levels in patients after radical prostatectomy are associated with me… (full text at CIViC) PMID 19244107 · Guo et al., 2009 · Open in CIViC	civic
(oncogenic)	Malignant Prostate Neoplasm	Oncogenic	D	Supports Oncogenicity	4	accepted	EID12258 Using a panel of three androgen-insensitive prostate cancer cell lines (C-81, CWR-R1 and 22Rv1), a novel AR protein isoform was identified. This protein was found to be encoded by three novel alternat… (full text at CIViC) PMID 19244107 · Guo et al., 2009 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Oncogenic	D	Supports Oncogenicity	4	accepted	EID12259 Seven novel AR isoforms were identified through the examination of cryptic exon splicing at exon 3 of the AR gene. All seven isoforms encode truncated AR proteins, lacking the ligand binding domain. T… (full text at CIViC) PMID 19117982 · Hu et al., 2009 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Oncogenic	D	Supports Oncogenicity	4	accepted	EID12465 To compare the activity of AR-V7 with that of full-length AR (AR-FL) lentiviral stable cell lines of castrate-resistant prostate cancer were generated that expressed doxycycline-regulated AR-V7 or AR-… (full text at CIViC) PMID 38687617 · Han et al., 2024 · Open in CIViC	civic
Abiraterone Acetate	Malignant Salivary Gland NeoplasmALIAS	Predictive	C	Supports Resistance	2	submitted	EID6954 Case Report of a Patient with metastatic salivary gland cancer with androgen receptor overexpression under treatment with abiraterone. The patient experienced stable disease for 6 months. Analysis of … (full text at CIViC) PMID 29897400 · Cappelletti et al., 2018 · Open in CIViC	civic
Abiraterone + EnzalutamideSubstitutes	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	accepted	EID9547 This multicenter clinical trial study (PROPHECY) enrolled 118 patients with metastatic castration-resistant prostate cancers (CRPC) on Abiraterone or Enzalutamide treatment. The Johns Hopkins Universi… (full text at CIViC) PMID 30865549 · Armstrong et al., 2019 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	submitted	EID9553 In a prospective clinical trial including 149 patients starting abiraterone or enzalutamide treatment AR-V7 expression is associated with worse PSA PFS, PFS and OS ( p < 0.001) in the overall cohort (… (full text at CIViC) PMID 28384066 · Antonarakis et al., 2017 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	accepted	EID12463 A cross-sectional cohort study was performed in 161 men with metastatic prostate cancer undergoing a change in treatment to determine if pre-therapy AR-V7 nuclear protein expression in circulating tum… (full text at CIViC) PMID 27262168 · Scher et al., 2016 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	accepted	EID12464 A blinded, multi-institutional cohort study was performed in 142 men with metastatic, castration-resistant prostate cancer to determine if pre-therapy nuclear-localized expression of AR-V7 protein in … (full text at CIViC) PMID 29955787 · Scher et al., 2018 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Predictive	B	Does Not Support Resistance	3	submitted	EID9548 A clinical study including 37 patients with mCRPC commencing abiraterone or enzalutamide treatment shows no significant changes in PSA PFS response when AR-V7 is expressed (p = 0.4). The same result i… (full text at CIViC) PMID 29398263 · To et al., 2018 · Open in CIViC	civic
Cabazitaxel	Malignant Prostate Neoplasm	Predictive	B	Does Not Support Resistance	4	submitted	EID9552 In a retrospective clinical study including 29 patients treated with cabazitaxel, AR-V7 expression is not significantly correlated with PSA response change (p = 0.6) or PFS (p = 0.8) or OS (p = 0.4 ).… (full text at CIViC) PMID 26188394 · Onstenk et al., 2015 · Open in CIViC	civic
Enzalutamide	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	submitted	EID9554 In a prospective clinical trial including 28 patients treated with enzalutamide, AR-V7 expression is significantly correlated with primary resistance (p = 0.018). PMID 24882673 · Efstathiou et al., 2015 · Open in CIViC	civic
Abiraterone + EnzalutamideSubstitutes	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	submitted	EID9555 In a prospective clinical trial including 37 patients treated with enzalutamide or abiraterone, AR-V7 expression is significantly associated with non PSA response to any subsequent treatment ( p < 0.0… (full text at CIViC) PMID 31289619 · Steinestel et al., 2019 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	4	submitted	EID9576 In a clinical study including 37 patients treated with taxanes or enzalutamide and abiraterone: - AR-V7 is associated with resistance to enzalutamide and abiraterone, but its relevance in the context … (full text at CIViC) PMID 26181238 · Antonarakis et al., 2015 · Open in CIViC	civic
〃	Malignant Prostate Neoplasm	Predictive	B	Supports Resistance	3	accepted	EID863 This prospective study enrolled 31 Enzalutamide-treated (group 1) and 31 Abiraterone-treated (group 2) patients with metastatic castration-resistant prostate cancers (CRPC). AR-V7 variant was detected… (full text at CIViC) PMID 25184630 · Antonarakis et al., 2014 · Open in CIViC	civic
Enzalutamide + GaleteroneSubstitutes	Malignant Prostate Neoplasm	Predictive	B	Supports Sensitivity Response	2	submitted	EID9549 In a clinical study including 38 AR-V7 positive patients treated with Galeterone (19) and Enzalutamide (19), PSA50 response rates is 13% for Galeterone and 42% for Enzalutamide. Open in CIViC	civic

AR OVEREXPRESSION2
Bicalutamide + LeuprolideCombination	Malignant Salivary Gland NeoplasmALIAS	Predictive	B	Supports Sensitivity Response	3	submitted	EID6953 In this single institution, open-label, single arm, phase II Trial, salivary gland carcinomas, staining positive for androgen receptor expression on IHC (minimum of 1% tumor cells), were treated with … (full text at CIViC) PMID 29211833 · Fushimi et al., 2018 · Open in CIViC	civic
Dactolisib	Malignant Breast Neoplasm	Predictive	D	Supports Sensitivity Response	3	accepted	EID859 In-vitro and xenograft studies of response of breast cancer cell lines to PI3K/mTOR inhibitor NVP-BEZ235 showed that sensitivity correlated with expression of the androgen receptor (AR). Reintroductio… (full text at CIViC) PMID 24356815 · Wang et al., 2014 · Open in CIViC	civic